表示全3结果
Retatrutide 10 mg is a next-generation triple-agonist peptide developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. This advanced multi-receptor approach distinguishes retatrutide from earlier weight-management compounds by targeting appetite control, insulin regulation, energy expenditure, and fat oxidation together, making it a key focus in metabolic and obesity research.
Retatrutide 30 mg is a next-generation triple-agonist peptide developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. This advanced multi-receptor approach distinguishes retatrutide from earlier weight-management compounds by targeting appetite control, insulin regulation, energy expenditure, and fat oxidation together, making it a key focus in metabolic and obesity research.
Tirzepatide is a synthetic dual-incretin peptide that mimics the activity of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—two hormones released by the gut after food intake. By activating both pathways, tirzepatide supports blood glucose regulation, appetite suppression, improved insulin response, and fat metabolism, making it a major focus in metabolic, diabetes, and weight-management research.
结束的内容
结束的内容
没有一个帐户吗？ 注册
